CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 900 target
Drug / intervention
PF-06821497 +2 moredrug
Likely dose
875 mgfrom record
Key inclusion· 5
  • ✓Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features
  • ✓Metastatic disease in bone or soft tissue documented on imaging
  • ✓Progressive disease despite medical or surgical castration
  • ✓ECOG performance status 0 or 1
Key exclusion· 7
  • ✕Medical or psychiatric condition making participant inappropriate for study
  • ✕Active inflammatory gastrointestinal disease, chronic diarrhea, or previous gastric resection or lap-band surgery
  • ✕Clinically significant cardiovascular disease
  • ✕History of myelodysplastic syndrome, acute myeloid leukemia, or other prior malignancy

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

In the news

1 article

Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.

Search/NCT06629779
NCT06629779Phase 3RecruitingHigh Momentum
CompareCT.gov

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

Pfizer·interventional·Posted Oct 8, 2024·Updated Jun 16, 2026

In Brief

A Phase 3 clinical trial evaluating PF-06821497, Placebo, and 1 other intervention for Metastatic Castration-Resistant Prostate Cancer. Currently recruiting, targeting 900 participants across 240 sites in 27 countries.

Signals

Enrolling ahead of pace

Detailed Summary

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Castration-Resistant Prostate Cancer
CountriesArgentina, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Netherlands, New Zealand, Poland, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Turkey (Türkiye), United Kingdom, United States
Collaborators--

Timeline

Phase 3Recruiting
20252026202720282029
First PostedOct 8, 2024
Enrollment StartOct 22, 2024
Primary CompletionDec 2, 2026
Study CompletionNov 30, 2028
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 1.7 years agoPrimary completion in 5 months

Arms & Interventions

Arm Aexperimental

Participants will receive PF-06821497 (875 mg) BID (twice daily) + enzalutamide 160 mg QD (once daily)

Drug: PF-06821497Drug: Enzalutamide
Arm Bactive_comparator

Participants will receive Placebo BID (twice daily) + enzalutamide 160 mg QD (once daily)

Drug: PlaceboDrug: Enzalutamide

Interventions

PF-06821497drug

Oral continuous

Placebodrug

Oral continuous

Enzalutamidedrug

Oral continuous